

SUPPLEMENT 30 dated 17th December, 2020
AMERICAN CENTURY ADVANCED MEDICAL IMPACT EQUITY FUND

Supplement 30 to the Prospectus of Nomura Funds Ireland plc,
dated 21st May 2020

This Supplement contains information relating specifically to the American Century Advanced Medical Impact Equity Fund (the "Sub-Fund"), a sub-fund of Nomura Funds Ireland plc (the "Fund"), an open-ended umbrella type investment company with segregated liability between each of its Sub-Funds, authorised by the Central Bank of Ireland (the "Central Bank") on 30th August, 2006 as a UCITS pursuant to the UCITS Regulations.

This Supplement forms part of and should be read in the context of and in conjunction with the Prospectus for the Fund dated 21st May, 2020 (the "Prospectus"), which immediately precedes this Supplement and is incorporated herein.

The Directors of the Fund whose names appear in the Prospectus under the heading "Management and Administration" accept responsibility for the information contained in this Supplement and the Prospectus. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this Supplement and in the Prospectus is in accordance with the facts and does not omit anything likely to affect the import of such information. The Directors accept responsibility accordingly.

An investment in the Sub-Fund should not constitute a substantial proportion of an investment portfolio and may not be appropriate for all investors. Investors should read and consider the section entitled "Risk Factors" before investing in the Sub-Fund.

Profile of a Typical Investor

The Sub-Fund is suitable for investors seeking long-term capital growth and who are prepared to accept a moderate level of volatility.

1. Interpretation

The expressions below shall have the following meanings:

| | |
|----------------|--|
| "Business Day" | means every day which is a bank business day in Dublin, London and New York excluding Saturdays and Sundays or such other day or days as may be determined by the Directors and notified to Shareholders in advance. |
| "Dealing Day" | means every Business Day or such other day or days as may be determined by the Directors and notified in advance to Shareholders provided that there shall be at least one Dealing Day in every two week period. |

| | |
|--|--|
| "Dealing Deadline" | means 13.00 Irish time on each Dealing Day or such other time as the Directors may determine and notify in advance to Shareholders provided always that the Dealing Deadline is no later than the Valuation Point. |
| "Equity and Equity-Related Securities" | includes but is not limited to equities, depository receipts, convertible securities (such as convertible preference shares) and preferred shares. |
| "Index" | means the MSCI World Healthcare Index. |
| "Index Country" | means a country which forms part of the Index. |
| "Valuation Point" | means 15.00 Irish Time on each Dealing Day or such other time as the Directors may determine and notify in advance to Shareholders provided always that the Dealing Deadline is no later than the Valuation Point. |

All other defined terms used in this Supplement shall have the same meaning as in the Prospectus.

2. Base Currency

The Base Currency of the Sub-Fund shall be US Dollars.

3. Available Classes

See Class Supplements.

4. Index

The MSCI World Health Care Index is designed to capture the large and mid-cap segments across 23 Developed Markets (DM) countries*. All securities in the index are classified in the Health Care as per the Global Industry Classification Standard (GICS®).

As at the date of the Prospectus the 23 DM countries are defined as Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, the UK and the US.

As at the date of this Prospectus, the administrator of the Index, namely MSCI appears on the register of administrators and benchmarks maintained by ESMA] pursuant to Article 36 of Regulation (EU) 2016/1011.

As required under the Benchmark Regulation, the Fund has put in place appropriate contingency arrangements setting out the actions which will be taken in the event that a benchmark which is used by the Sub-Fund which is subject to the Benchmark Regulation materially changes or ceases

to be provided. A copy of the Fund's policy on cessation or material change to a benchmark is available upon request from the Fund.

5. Investment Objective

The investment objective of the Sub-Fund is to achieve long-term capital growth through investment in an actively managed portfolio of equity securities of companies engaged in the health care sector.

6. Investment Policy

The Sub-Fund will invest, under normal market conditions, primarily in Equity and Equity-Related Securities of companies engaged in the health care sector, which are listed or traded on a Recognised Exchange and which companies may be selected from the Index.

The Sub-Fund will consist of health care companies, which are companies classified in the health care category as per the Global Industry Classification Standard (GICS®) and / or those companies that otherwise, in the opinion of the Investment Manager, promote the philosophy of healthy lives and well-being for all and are innovative and capable of sustainable business development ("Health Care Companies"), as further set out in the "Investment Strategy" below.

The Sub-Fund may gain exposure to the Index directly or through investment in such instruments as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) and which may be listed on any Recognised Exchange in a non-Index Country (as further described in the sub-section "Investments in ADRs and GDRs" under "Additional Risk Factors" below).

The Sub-Fund may also invest up to 30% of its Net Asset Value in Health Care Companies outside the Index, such as lower cap Health Care Companies (including companies with capitalization as low as \$500 million at purchase) and Health Care Companies located in emerging countries, such as China. The Sub-Fund may gain exposure to China by investment in Chinese A shares of issuers which are engaged in the health care sector and which are traded via Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect. Chinese A shares are renminbi-denominated A shares of companies domiciled in mainland China; these are traded on Chinese stock exchanges such as the Shanghai Stock Exchange and the Shenzhen Stock Exchange (as further described in the sub-section headed "Risks associated with the Stock Connect Scheme" under "Additional Risk Factors" below).

The Sub-Fund will be managed so as to maintain a near fully invested position in Equity and Equity-Related Securities, other than during periods where the Investment Manager believes that a larger cash position is warranted.

In the event of exceptional market or economic conditions, the Sub-Fund may also invest up to 10% of net assets in both investment grade and non-investment grade debt and debt-related securities comprising notes (such as short term treasury notes), bonds, preferred securities, (such bonds with hybrid features and characteristics of both bonds and equities which are in

general perpetual and callable, and pay fixed-rate or floating-rate dividends instead of coupons and rank higher than common stocks but lower than senior debt), zero coupon, pay-in-kind or deferred payment securities, variable and floating rate instruments (debt securities with floating coupon rates whereby the interest paid to an investor fluctuates over time with an underlying interest rate level, such as floating rate notes) issued by governments, governmental agencies or corporates. Investment grade securities are those that have been rated in one of the four highest categories used by a nationally recognised statistical rating organisation or determined by the Investment Manager to be of comparable credit quality. Non-investment grade securities are those that have been rated below the four highest categories used by a nationally recognised statistical rating organisation, or, if not rated, determined by the Investment Manager to be of similar quality (which assessment is made by the Investment Manager reviewing the credit attributes of the issuer of the security, such as its financial strength (profitability, cash flows, liquidity, leverage etc.) business profile, management quality as well as the political, legal and regulatory environment).

The Sub-Fund may also invest up to 10% in other eligible collective investment schemes, including exchange-traded funds. The Sub-Fund may also invest in closed-ended exchange traded funds provided any such investment is in accordance with the investment limits for investment in transferable securities, as appropriate, and as set out in Appendix I to the Prospectus.

The Sub-Fund may also, in accordance with the investment powers and restrictions set out in Appendix I of the Prospectus, use financial derivative instruments for efficient portfolio management and/or hedging, as set out below under “Use of Derivatives”.

The Sub-Fund is actively managed in reference to the Index by virtue of the fact that it uses the Index for performance comparison purposes. Certain of the Sub-Fund’s securities may be components of and may have similar weightings to the Index. However, as noted above, the Sub-Fund may deviate up to 30% from the Index and the Investment Manager may use its discretion to invest in companies or sectors not included in the Index.

Investment Strategy

The portfolio is constructed with a dual mandate: to create long-term excess returns primarily through stock selection and a positive societal impact from the portfolio companies achieving fundamental advancement in the medical industry. The Investment Manager believes that their investment team can generate superior returns over the Index by being more long-term oriented during short-term market disruptions and by being unconstrained by these behavioural limitations. It also believes that the health care sector offers significant long-term growth opportunities due to demographic shifts and the rapid pace of innovation.

The Investment Manager employs a three-step process while identifying suitable investments for the Sub-Fund: 1) proprietary model ranking, 2) fundamental analysis, and 3) portfolio construction.

Proprietary Model Ranking

First, the Investment Manager will screen the around 700 Health Care Companies which make

up the investment universe of the Sub-Fund, using a proprietary quantitative model ranking tool that ranks stocks based on fundamental acceleration (e.g., sales or earnings growth), earnings quality (e.g., balance sheet, profitability/margins, and cashflow metrics), relative strength (e.g., stock price momentum) and valuation to narrow the universe down to 100-150 stocks. The Investment Manager also may generate investment ideas through company meetings, industry contacts, medical conferences, and scientific literature.

Fundamental Analysis

Next, the Investment Manager's investment team then conducts deep fundamental research on health care companies to identify and confirm the quality of the company, the drivers of acceleration, sustainability of growth and profitability. The Investment Manager looks to invest in Equity and Equity-Related Securities of Health Care Companies it believes will increase in value over time. The Investment Manager believes that stocks of companies are well-positioned to outperform when there is acceleration in the company's fundamental business trends, valuations are attractive, and the stock is demonstrating relative strength. The Investment Manager makes investment decisions based primarily on its analysis of individual Health Care Companies, rather than on economic forecasts. It believes in buying "high quality" or "good" businesses, which include high return on capital companies that are well established and currently have superior market positions or have the potential to become industry leaders. The Investment Manager conducts rigorous and differentiated fundamental research in its attempt to recognize Health Care Companies early in their life cycle by looking for accelerating rates of change in both earnings and revenues, combined with improving relative stock price performance, and to more accurately assess a company's competitive position and growth prospects. By acting quickly and decisively in response to changes in a company's financial condition and earnings trend, the Investment Manager believes it can exploit the market's tendency to incrementally recognize the long-term implications of a company's improving or deteriorating business conditions.

The Investment Manager's analysis of a Health Care Company's impact on society is fully integrated into this step. The Investment Manager believes that companies that offer high potential impact to society are the ones more likely to outperform financially over the long term. More specifically, the Investment Manager looks for Health Care Companies that offer innovative solutions for unmet medical needs and those that improve access, increase efficiency, and lower cost for health care. Health Care Companies that can provide these products and services are attractive both from a financial perspective and a societal impact perspective. Therefore, all of the stocks selected for the portfolio will meet at least one of the UN Sustainable Development Goals, which is the primary way the team defines "impact."

During this step of the investment-decision making process, the Investment Manager's internal ESG team also evaluates and factors in a Health Care Company's long-term impact on environment, society and governance (ESG). For example, the Investment Manager, based on its proprietary methodology, assigns weights to each of the ESG factors, calculates a composite score for each Health Care Company using the weighted factors, and then ranks the Health Care Companies based on their composite scores. The Investment Manager believes that a company with a strong ESG profile is better positioned for future challenges, which should strengthen its long-term corporate fundamentals.

The Investment Manager has a dedicated team that provides analysis on ESG risks impacting each portfolio holding. Individual portfolio positions are weighted according to the level of conviction determined by the Investment Manager. The ESG team monitors portfolio holdings for potentially material ESG risks as well as ESG controversies on an ongoing basis. Examples of ESG risks include climate change and water stress at the physical level (asset integrity) and transitional level (stranded assets such as coal and hydrocarbons which have the potential to suffer a premature devaluation/phase out due to the risks they pose to the environment, environmental compliance risk and negative externalities); operational safety rates; product recalls and related litigation costs; cybersecurity risk; labor/workflow disruption, and supply chain issues. Examples of ESG controversies include governance risks including business conduct (corruption and fraud), changes in accounting estimates or restatements, board independence and entrenchment/overboarding level, executive pay-for-performance alignment, and incident related issues that denote failures of a company to address and mitigate associated ESG risks. The investment team of the Investment Manager can also address with company management any ESG issues and controversies identified by the Investment Manager's ESG investment team and deemed material to an issuer's long-term financial condition. If the Investment Manager's ESG team assessments identify a company as exposed to ESG issues that are based on verifiable data and that are material to the company's financial condition, the ESG team makes a recommendation to engage with company management. If the Investment Manager engages with the company's management, it will consider the outcome of such engagement in its investment-decision making process.

Portfolio Construction

Lastly, the Investment Manager constructs the Sub-Fund's portfolio by referencing liquidity constraints, risk management guidelines and growth-oriented performance trends. The liquidity constraints referenced by the Investment Manager are based on the number of days the Investment Manager determines is required to fully sell each security held by the Sub-Fund without substantially impacting the market price of each such security. The Investment Manager employs a strong "sell" discipline whereby it ensures that once a stock meets certain criteria, such as price or risk targets, the stock is either partially or fully sold from the Sub-Fund.

General

Any changes to the investment objective of the Sub-Fund and any material changes to the investment policy may not be made without the prior written approval of all Shareholders or approval on the basis of a majority of votes cast at a general meeting of Shareholders of the Sub-Fund. Any such changes may not be made without the approval of the Central Bank. In the event of a change in investment objective and/or a change to the investment policy, a reasonable notification period will be provided by the Fund to enable Shareholders to redeem their Shares prior to implementation of such change.

The Sub-Fund will, on request, provide to Shareholders supplementary information relating to the risk management methods employed, including the quantitative limits that are applied and any recent developments in the risk and yield characteristics of the main categories of investments.

The Sub-Fund's investments are subject to the investment restrictions as set out in Appendix I to the Prospectus.

A list of the stock exchanges and markets in which the Sub-Fund is permitted to invest, in accordance with the requirements of the Central Bank, is contained in Appendix II to the Prospectus and should be read in conjunction with, and subject to, the Sub-Fund's investment objective and investment policy, as detailed above. The Central Bank does not issue a list of approved markets. Other than permitted investments in unlisted securities and over the counter derivative instruments, any other investment will be restricted to those stock exchanges and markets listed in Appendix II to the Prospectus.

There can be no assurance that the Sub-Fund will achieve its investment objective or avoid substantial losses.

Share Class Currency Hedging

Foreign exchange transactions may be used for currency hedging purposes. A Share Class of the Sub-Fund which is denominated in a currency other than the Base Currency may be hedged against exchange rate fluctuation risks between the denominated currency of the Share Class and the Base Currency of the Sub-Fund. The Investment Manager may attempt to mitigate the risk of such fluctuation by using forward currency contracts, for currency hedging purposes, subject to the conditions and within the limits laid down by the Central Bank. Where a Class of Shares is to be hedged using such instruments (a "Hedged Share Class"), this will be disclosed in the relevant Class Supplement. While it is not intended that a Hedged Share Class will be leveraged, the use of hedging techniques and instruments may result in a Hedged Share Class being over or under hedged due to external factors outside the control of the Company, subject to the requirements of the Central Bank. To the extent that leverage is employed, leverage will be measured using the commitment approach of measuring risk.

Use of Derivatives

The Sub-Fund may employ (subject to the conditions and within the limits laid down by the Central Bank) financial derivative instruments and techniques for efficient portfolio management and/or hedging. Efficient portfolio management transactions may be entered into by the Investment Manager with one of the following aims a) a reduction of risk b) a reduction of cost with no increase or a minimal increase in risk; c) generation of additional capital or income with no, or an acceptably low level of risk (relative to the expected return).

The financial derivative instruments and techniques which may be used by the Sub-Fund for efficient portfolio management and/or to hedging are futures and forward currency contracts.

Futures

Futures are contracts to buy or sell a standard quantity of a specific underlying at a pre-determined future date and at a price agreed through a transaction undertaken on an

exchange. Futures may also be cash settled. Futures contracts allow investors to hedge against risk or gain exposure to the underlying asset (details of which are set out below). Since these contracts are marked-to-market daily, investors can, by closing out their position, exit from their obligation to buy or sell the underlying prior to the contract's expiry date. Futures may be used where its market access is easier, more liquid or more cost-efficient than direct exposure to the underlying itself.

The Fund may use the following futures:

- Foreign exchange futures which may be used to take a long position in or hedge a currency exposure. For example in order to express the view that the USD will depreciate against the EUR, the Investment Manager may choose to enter into a long EUR short USD future.
- Index futures which may be used to take long exposure to a particular index such as an equity index. For example, in order to express a positive view on U.S. stocks the Investment Manager may choose to go long an S&P 500 future.
- Equity futures may be used to purchase or sell a stock on a specified date at a predetermined price, for example instead of buying a certain stock outright in physical format the Investment Manager may choose to go long a future on such stock.
- Dividend futures allow the Investment Manager to take positions on future dividend payments on a single company, a basket of companies or on an equity index. Dividend futures may be used to take a long position in dividends, for example in order to express a positive view on dividends the Investment Manager may choose to go long a dividend future.

Forwards

The Fund may also enter into forward contracts. In a forward the contract holders are obliged to buy or sell a particular underlying at a specified price in a specified quantity and on a specified future date. Forwards may also be cash settled. In contrast to futures, forwards are not traded on an exchange, but in the OTC market. Forward contracts may be used to hedge or generate exposure. They can be used to express both positive and negative views on the underlying assets, hence they can create a synthetic short position.

The Fund may use foreign exchange forwards. Foreign exchange forwards may be used to hedge or take a long position in a currency exposure, for example in order to express the view that a the USD will depreciate against the EUR the Investment Manager may choose to enter into a long EUR short USD forward.

The use of futures and forwards by the Sub-Fund may create leverage. To the extent that leverage is employed, leverage will be measured using the commitment approach of measuring risk, whereby such leverage cannot exceed 100 per cent of the Net Asset Value of the Sub-Fund. In practise, it is anticipated that the use of financial derivative instruments by the Sub-Fund will be minimal and, therefore, the actual level of leverage will be in the region of 0% to

10% of the Net Asset Value of the Sub-Fund. It is possible that the Sub-Fund may be leveraged up to 100% of Net Asset Value at any point in time.

It is expected that the use of financial derivative techniques and instruments may increase the Sub-Fund's risk level.

Securities Financing Transactions

The Sub-Fund may enter into repurchase agreements and/or securities lending agreements for efficient portfolio management purposes only where the objective of using such instruments is to hedge against risk and/or to reduce costs borne by the Sub-Fund or to generate additional capital or income which is consistent with the risk profile of the Sub-Fund and the risk diversification rules set down in the UCITS Regulations.

All types of assets which may be held by the Sub-Fund in accordance with its investment objectives and policies may be subject to a securities financing transaction.

The maximum proportion of the Sub-Fund's assets which can be subject to securities financing transactions is 100% of the Net Asset Value of the Sub-Fund. However, the expected proportion of the Sub-Fund's assets which will be subject to securities financing transactions is between 0% and 20% of the Net Asset Value of the Sub-Fund's assets in the case of securities lending agreements and between 0% and 10% in the case of repurchase agreements. The proportion of the Sub-Fund's assets which are subject to securities financing transactions at any given time will depend on prevailing market conditions and the value of the relevant investments. The amount of assets engaged in each type of securities financing transactions, expressed as an absolute amount and as a proportion of the Sub-Fund's assets, as well as other relevant information relating to the use of securities financing transactions shall be disclosed in the annual report and semi-annual report of the Fund.

Further information relating to securities financing transactions is set out in the Prospectus at the sections entitled "*Securities Financing Transactions*".

7. Sub-Investment Manager

The Investment Manager has delegated the investment management function to American Century Investment Management, Inc. (the "Sub-Investment Manager") pursuant to a Sub-Investment Management Agreement dated as of 1st April, 2019 as amended from time to time between the Investment Manager and the Sub-Investment Manager. The Sub-Investment Manager is a U.S.-based investment manager registered with and regulated by the U.S. Securities and Exchange Commission. The Sub-Investment Manager shall not be paid directly out of the Sub-Fund.

The Sub-Investment Management Agreement provides that the Sub-Investment Manager will manage the assets of the Sub-Fund in conformity with the investment objectives and investment policies of the Sub-Fund as set out in this Supplement and within the investment restrictions set out in Appendix I to the Prospectus.

8. Additional Risk Factors

The attention of investors is drawn to the “Risk Factors” in the Section of the Prospectus entitled “The Fund”. In addition, investors should be aware of the following risks applicable to the Sub-Fund.

Investment in Emerging Markets

Investing in emerging markets involves risks and special considerations not typically associated with investing in other more established economies or securities markets. Investors should carefully consider their ability to assume the risks listed below before making an investment in the Sub-Fund. Investing in emerging markets is considered speculative and involves the risk of total loss. Because the Sub-Fund's investments will be subject to the market fluctuations and risks inherent in all investments, there can be no assurance that the Sub-Fund's stated objective will be realised. The Sub-Fund's Investment Manager will seek to minimize these risks through professional management and investment diversification. As with any long-term investment, the value of shares when sold may be higher or lower than when purchased.

Risks of investing in emerging markets include:

1. The risk that the Sub-Fund's assets may be exposed to nationalization, expropriation, or confiscatory taxation;
2. The fact that emerging market securities markets are substantially smaller, less liquid and more volatile than the securities markets of more developed nations. The relatively small market capitalization and trading volume of emerging market securities may cause the Sub-Fund's investments to be comparatively less liquid and subject to greater price volatility than investments in the securities markets of developed nations. Many emerging markets are in their infancy and have yet to be exposed to a major correction. In the event of such an occurrence, the absence of various market mechanisms, which are inherent in the markets of more developed nations, may lead to turmoil in the marketplace, as well as the inability of the Sub-Fund to liquidate its investments;
3. Greater social, economic and political uncertainty (including the risk of war);
4. Greater price volatility, substantially less liquidity and significantly smaller market capitalization of securities markets;
5. Currency exchange rate fluctuations and the lack of available currency hedging instruments;
6. Higher rates of inflation;
7. Controls on foreign investment and limitations on repatriation of invested capital and on the Sub-Fund's ability to exchange local currencies for U.S. dollars;
8. Greater governmental involvement in and control over the economy;
9. The fact that emerging market companies may be smaller, less seasoned and newly organised;
10. The difference in, or lack of, auditing and financial reporting standards that may result in unavailability of material information about issuers;
11. The fact that the securities of many companies may trade at prices substantially above

- book value, at high price/earnings ratios, or at prices that do not reflect traditional measures of value;
12. The fact that statistical information regarding the economy of many emerging market countries may be inaccurate or not comparable to statistical information regarding the United States or other economies;
 13. Less extensive regulation of the securities markets;
 14. The maintenance of Sub-Fund portfolio securities and cash with foreign sub-custodians and securities depositories;
 15. The risk that it may be more difficult, or impossible, to obtain and/or enforce a judgment than in other countries;
 16. The risk that the Sub-Fund may be subject to income, capital gains or withholding taxes imposed by emerging market countries or other foreign governments;
 17. The risk that enterprises in which the Sub-Fund invests may be or become subject to unduly burdensome and restrictive regulation affecting the commercial freedom of the invested company and thereby diminishing the value of the Sub-Fund's investment in that company. Restrictive or over regulation may therefore be a form of indirect nationalization;
 18. The risk that businesses in emerging markets have only a very recent history of operating within a market-oriented economy. In general, relative to companies operating in developed economies, companies in emerging markets are characterised by a lack of (i) experienced management, (ii) technology, and (iii) sufficient capital base with which to develop and expand their operations. It is unclear what will be the effect on companies in emerging markets, if any, of attempts to move towards a more market-oriented economy; and
 19. Disposition of illiquid securities often takes more time than for more liquid securities, may result in higher selling expenses and may not be able to be made at desirable prices or at the prices at which such securities have been valued by the Sub-Fund.

Investments in ADRs and GDRs

American Depository Receipts (ADRs) are depository receipts typically issued by a U.S. bank or trust company that evidence ownership of underlying equity securities issued by a foreign corporation. Global Depository Receipts (GDRs) are typically issued by foreign banks or trust companies, although they also may be issued by U.S. banks or trust companies, and evidence ownership of underlying equity securities issued by either a foreign or a United States corporation. Generally, depository receipts in registered form are designed for use in the U.S. securities market, and depository receipts in bearer form are designed for use in securities markets outside the United States. For purposes of the Sub-Fund's investment policies, the Sub-Fund's investments in depository receipts will be deemed investments in the underlying securities.

Risks associated with the Stock Connect Scheme

The Sub-Fund may invest in China A shares through the Shanghai Hong Kong Stock Connect scheme, or the Shenzhen Hong Kong Stock Connect scheme (the "Stock Connect Scheme").

The Shanghai Hong Kong Stock Connect is a securities trading and clearing linked program developed by Hong Kong Exchanges and Clearing Limited ("HKEx"), the Shanghai Stock

Exchange (“SSE and China Securities Depository and Clearing Corporation Limited (“ChinaClear”). The Shenzhen Hong Kong Stock Connect is a securities trading and clearing links program developed by HKEx, Shenzhen Stock Exchange (“SZSE”) and ChinaClear.

The aim of the Stock Connect is to achieve mutual stock market access between Mainland China and Hong Kong. The stock exchanges of the two jurisdictions continue to issue details of Stock Connect, e.g. operational rules, from time to time. The Stock Connect enables investors to trade eligible shares listed on the other’s market through local securities firms or brokers.

The Stock Connect comprises Northbound Trading Links and Southbound Trading Links. Under the Northbound Trading Links, investors, through their Hong Kong brokers and a securities trading service company to be established by the Stock Exchange of Hong Kong Limited (“SEHK”), are able to place orders to trade eligible China A shares listed on the relevant PRC Stock Exchange (“Stock Connect Securities”) by routing orders to such PRC stock exchange. All Hong Kong and overseas investors (including the Sub-Fund) are allowed to trade Stock Connect Securities through the Stock Connect (through the relevant Northbound Trading Link).

Stock Connect Securities

There can be no assurance that an active trading market for such Stock Connect securities will develop or be maintained. If spreads on Stock Connect securities are wide, this may adversely affect the Sub-Fund’s ability to dispose of such securities at the desired price. If the Sub-Fund needs to sell Stock Connect securities at a time when no active market for them exists, the price it receives for its Stock Connect securities - assuming it is able to sell them - is likely to be lower than the price received if an active market did exist, and thus the performance of the Sub-Fund may be adversely affected depending on the Sub-Fund’s size of investment in securities through the Stock Connect.

Quota Limitations

The Stock Connect scheme (“Connect Scheme”) is subject to quota limitations which may restrict the Sub-Fund’s ability to invest in China A-Shares through the programme on a timely basis and as a result, the Sub-Fund’s ability to access the China A-Shares market (and hence to pursue its investment strategy) may be adversely affected.

Trading under the Connect Scheme will be subject to the daily quota. The daily quota may change and consequently affect the number of permitted buy trades on the relevant Northbound Trading Link. The Sub-Fund does not have exclusive use of the daily quota and such quotas are utilised on a “first come – first served” basis. Therefore, quota limitations may restrict the Sub-Fund’s ability to invest in or dispose of China Connect Securities through the Connect Scheme on a timely basis.

Clearing and Settlement Risk

The Stock Connect infrastructure involves two central securities depositories - Hong Kong Securities Clearing Company Limited (“HKSCC”) and China Securities Depository & Clearing Corporation Limited (“ChinaClear”). HKSCC and ChinaClear have established the clearing links and each becomes a participant of each other to facilitate clearing and settlement of cross-border trades. For cross-border trades initiated in a market, the clearing house of that market will on one hand clear and settle with its own clearing participants, and on the other hand undertake to fulfil the clearing and settlement obligations of its clearing participants with the counterparty clearing house.

The Sub-Fund's rights and interests in China Connect Securities will be exercised through HKSCC exercising its rights as the nominee holder of China Connect Securities credited to HKSCC's omnibus account with ChinaClear. The relevant measures and rules in relation to the Stock Connect Scheme generally provide for the concept of a “nominee holder” and recognise the investors including the Sub-Fund as the “beneficial owners” of the Stock Connect securities.

However, the precise nature and rights of an investor as the beneficial owner of China Connect Securities through HKSCC as nominee is less well defined under PRC law. There is lack of a clear definition of, and distinction between, “legal ownership” and “beneficial ownership” under PRC law. Therefore, the Sub-Fund's assets held by HKSCC as nominee (via any relevant brokers' or custodians' accounts in CCASS) may not be as well protected as they would be if it were possible for them to be registered and held solely in the name of the Sub-Fund.

In connection to this, in the event of a default, insolvency or bankruptcy of a custodian or broker, the Sub-Fund may be delayed or prevented from recovering its assets from the custodian or broker, or its estate, and may have only a general unsecured claim against the custodian or broker for those assets.

In the remote event of any settlement default by HKSCC, and a failure by HKSCC to designate securities or sufficient securities in an amount equal to the default such that there is a shortfall of securities to settle any securities trades, ChinaClear may deduct the amount of that shortfall from HKSCC's omnibus account with ChinaClear, such that the Sub-Fund may share in any such shortfall.

HKSCC is the nominee holder of the securities acquired by investors via Stock Connect. As a result, in the remote event of a bankruptcy or liquidation of HKSCC, the Stock Connect securities may not be regarded as the general assets of HKSCC under the laws of Hong Kong, and will not be available to the general creditors of HKSCC on its insolvency. In addition, as a Hong Kong incorporated company, any insolvency or bankruptcy proceedings against HKSCC will be initiated in Hong Kong and be subject to Hong Kong law. In such circumstances, ChinaClear and the courts of mainland China will regard the liquidator of HKSCC appointed under Hong law as the entity with the power to deal with the relevant securities in place of HKSCC.

PRC Tax Laws

There are risks and uncertainties associated with the current PRC tax laws, regulations and practice in respect of capital gains realised via Stock Connect on the Sub-Fund's investments in the PRC (which may have retrospective effect). Any changes in PRC tax law, future clarifications thereof, and/or subsequent retroactive enforcement by the PRC tax authorities of capital gains tax may increase tax liabilities on the Sub-Fund and result in a material loss to the Sub-Fund.

The Investment Manager may, in its discretion from time to time (in consultation with the Depository), make a provision for potential tax liabilities, if in their opinion such provision is warranted, or as further clarified by the PRC in notifications.

9. Application for Shares

Applications for Shares may be made to the Administrator on behalf of the Fund. Applications must be received by the Administrator by no later than 13.00 (Irish time) on the last day of the Initial Offer Period or thereafter by the Dealing Deadline for the relevant Dealing Day. Applications accepted by the Administrator on behalf of the Fund and received prior to the Dealing Deadline for any Dealing Day will be processed on that Dealing Day. Any applications received after the Dealing Deadline for a particular Dealing Day will be processed on the following Dealing Day unless, in exceptional circumstances, the Directors in their absolute discretion otherwise determine to accept one or more applications received after the Dealing Deadline for processing on that Dealing Day provided that such application(s) have been received prior to the Valuation Point for the particular Dealing Day.

Initial account opening applications should be made using an Application Form obtained from the Administrator or the Distributor but may, if the Administrator so determines, be made by telefax or scanned copies via electronic e-mail. Other papers (such as documentation relating to money laundering prevention checks) may additionally be required by the Directors or their delegate. Applications to purchase Shares following the initial account opening may only be made to the Administrator by STP (straight through processing) method, telefax or written communication (excluding telephone orders) or such other means as may be permitted by the Directors (which, for the avoidance of doubt, shall exclude electronic e-mail) and such applications should contain such information as may be specified from time to time by the Directors or their delegate. Amendments to a Shareholder's bank details will only be made following receipt of original written instructions from the relevant Shareholder. Amendments to other registration details may be made following the receipt of written instructions via telefax or mail.

Fractions

Subscription monies representing less than the subscription price for a Share will not be returned to the investor. Fractions of Shares will be issued where any part of the subscription

monies for Shares represents less than the subscription price for one Share, provided however, that fractions shall not be less than .0001 of a Share.

Subscription monies, representing less than .0001 of a Share will not be returned to the investor but will be retained by the Fund in order to defray administration costs.

Method of Payment

Subscription payments net of all bank charges should be paid by CHAPS, SWIFT or telegraphic or electronic transfer to the bank account specified in the Application Form. Other methods of payment are subject to the prior approval of the Directors. No interest will be paid in respect of payments received in circumstances where the application is held over until a subsequent Dealing Day.

Currency of Payment

Subscription monies are payable in the currency of the Share Class. However, the Sub-Fund may accept payment in such other currencies as the Fund may agree at the prevailing exchange rate quoted by the Administrator. The cost and risk of converting currency will be borne by the investor.

Timing of Payment

Payment in respect of subscriptions must be received in cleared funds by the Administrator no later than three (3) Business Days after the end of the Initial Offer Period or the relevant Dealing Day (as the case may be) provided that the Fund reserves the right to defer the issue of Shares until receipt of cleared subscription monies by the Fund. If payment in cleared funds in respect of a subscription has not been received by the relevant time, the Fund or its delegate may (and in the event of non-clearance of funds, shall) cancel the allotment and/or charge the investor interest at the 7 day London Interbank Offer Rate as fixed by the British Banking Association (LIBOR) + 1%, which will be paid into the Sub-Fund together with an administration fee which shall be representative of the custody fees incurred as a result of the late payment (which shall be at normal commercial rates). The Fund may waive either of such charges in whole or in part. In addition, the Fund has the right to sell all or part of the investor's holding of Shares in the Sub-Fund or any other sub-fund of the Fund in order to meet such charges.

Confirmation of Ownership

Confirmation of each purchase of Shares will be sent to Shareholders within 24 hours of the purchase being made. Title to Shares will be evidenced by the entering of the investor's name on the Fund's register of Shareholders and no certificates will be issued.

10. Redemption of Shares

Requests for the redemption of Shares should be made to the Administrator on behalf of the Fund by facsimile or written communication (excluding telephone orders) or such other means

as may be permitted by the Directors (which, for the avoidance of doubt, shall exclude electronic e-mail) and should include such information as may be specified from time to time by the Directors or their delegate.

Redemption requests should be sent to the Administrator to be received by the Dealing Deadline for the relevant Dealing Day. Requests for redemption received prior to the Dealing Deadline for any Dealing Day will be processed on that Dealing Day. Any requests for redemption received after the Dealing Deadline for a Dealing Day will be processed on the next Dealing Day unless, in exceptional circumstances, the Directors in their absolute discretion otherwise determine to accept one or more requests received after the Dealing Deadline for processing on that Dealing Day provided that such request(s) have been received prior to the Valuation Point for the particular Dealing Day.

Redemption requests will only be accepted for processing where cleared funds and completed documents including documentation relating to money laundering prevention checks are in place from original subscriptions. No redemption payment will be made from an investor holding until the original subscription application form and all documentation required by or on behalf of the Fund (including any documents in connection with anti-money laundering procedures) has been received from the investor and the anti-money laundering procedures have been completed.

If the number of Shares to be redeemed on any Dealing Day equals one tenth or more of the total number of Shares of the Sub-Fund in issue on that day, the Directors shall have the right to limit redemption, as more particularly set out under the heading "Redemption of Shares" in the Prospectus.

The minimum value of Shares which a Shareholder may redeem in any one redemption transaction is the Minimum Transaction Size specified in the relevant Class Supplement. In the event of a Shareholder requesting a redemption which would, if carried out, leave the Shareholder holding Shares having a Net Asset Value less than the Minimum Holding, the Fund may, if it thinks fit, redeem the whole of the Shareholder's holding.

Method of Payment

Redemption payments will be made to the bank account detailed on the Application Form or as subsequently notified to the Administrator in writing. Redemption payments following processing of instructions received by facsimile will only be made to the account of record of a Shareholder.

Currency of Payment

Shareholders will normally be repaid in the currency of their Share Class. If, however, a Shareholder requests to be repaid in any other freely convertible currency, the necessary foreign exchange transaction may be arranged by the Administrator (at its discretion) on behalf of and for the account, risk and expense of the Shareholder.

Timing of Payment

Redemption proceeds in respect of Shares will normally be paid within three (3) Business Days after the relevant Dealing Day, provided that all the required documentation has been furnished to and received by the Administrator.

Withdrawal of Redemption Requests

Requests for redemption may not be withdrawn save with the written consent of the Fund or its authorised agent or in the event of suspension of calculation of the Net Asset Value of the Fund or the relevant Class.

Compulsory/Total Redemption

Shares of the Sub-Fund may be compulsorily redeemed and all the Shares may be redeemed in the circumstances described in the Prospectus under the sub-headings "Compulsory Redemption of Shares" and "Total Redemption".

11. Conversion of Shares

Subject to the Minimum Subscription and Minimum Holding requirements of the relevant Sub-Fund or Class, Shareholders may request conversion of some or all of their Shares in one Sub-Fund or Class to Shares in another Sub-Fund or Class or another Class in the same Sub-Fund in accordance with the procedures specified in the Prospectus under the heading "Conversion of Shares".

12. Suspension of Dealing

Shares may not be issued, redeemed or converted during any period when the calculation of the Net Asset Value of the Sub-Fund or the relevant Class is suspended in the manner described in the Prospectus under the heading "Suspension of Valuation of Assets". Applicants for Shares and Shareholders requesting redemption and/or conversion of Shares will be notified of such suspension and, unless withdrawn, applications for Shares will be considered and requests for redemption and/or conversion will be processed as at the next Dealing Day following the ending of such suspension.

13. Fees and Expenses

The Sub-Fund shall bear (i) the fees and expenses relating to the establishment of the Sub-Fund, estimated to amount to Euro 15,000, which may be amortised over the first five Accounting Periods of the Sub-Fund or such other period as the Directors may determine and in such manner as the Directors in their absolute discretion deem fair; and (ii) its attributable portion of the fees and operating expenses of the Fund. The fees and operating expenses of the Fund are set out in detail under the heading "Fees and Expenses" in the Prospectus. The fees and expenses relating to the establishment of the Fund have been fully amortised.

Investment Management Fees

An Investment Management Fee may be payable out of the assets of the Sub-Fund at a rate per annum (as set out in the relevant Class Supplement) of the daily Net Asset Value of each Class of Shares, before deduction of fees, expenses, borrowings and interest. The Investment Management Fee is calculated and accrued daily and payable quarterly in arrears. The Investment Manager shall be entitled to be reimbursed by the Sub-Fund for reasonable out of pocket expenses incurred by it and any VAT on fees and expenses payable to or by it.

The Investment Manager may also be entitled to an Incentive Fee payable in arrears in respect of the Sub-Fund, as specified in the relevant Class Supplement.

Sales Charge

The Distributor may charge Shareholders a sales charge of up to 5% of the Net Asset Value per Share held by a Shareholder. Such commission shall be payable to the Distributor. The sales charge (if any) for each Class of Share is set out in the relevant Class Supplement.

Redemption Fee

The redemption price per Share shall be the Net Asset Value per Share. It is not the current intention of the Directors to charge a redemption fee generally. The Directors will give not less than three months' notice to Shareholders of their intention to introduce a redemption fee generally. However, the Directors are empowered to charge a redemption fee of up to 3% as set out under the section headed "Abusive Trading Practices/Market Timing" on page 63 of the Prospectus and may exercise their discretion in this respect if they have reason to believe that any Shareholder requesting redemption is attempting any form of arbitrage on the yield of Shares in the Fund.

In the event of a sales charge and/or a redemption fee being charged, Shareholders should view their investment as medium to long term.

14. Dividends and Distributions

The Sub-Fund is an accumulating Sub-Fund and, therefore, it is not currently intended to distribute dividends to the Shareholders. The income and earnings and gains of the Sub-Fund will be accumulated and reinvested on behalf of Shareholders.

The Directors may at any time determine to change the policy of the Sub-Fund with respect to distribution. If the Directors so determine, full details of any such change will be disclosed in an updated Prospectus or Supplement and all Shareholders will be notified in advance of such change becoming effective.

15. Transfer Restrictions

Shares in the Sub-Fund have not been and will not be registered under the Securities and Exchange Law of Japan or with any securities regulatory authority in Japan. Shares may not be offered or sold, directly or indirectly in Japan or to or for the benefit of any resident of Japan, except as permitted by applicable Japanese law.

16. Taxation

Potential investors and Shareholders are referred to the section headed "Taxation" on page 79 of the Prospectus which contains summaries of Irish, United Kingdom and German taxation law and practice relevant to the transactions contemplated in the Prospectus. As this Supplement forms part of the Prospectus, potential investors and Shareholders are advised to read this section of the Supplement in conjunction with the section headed "Taxation" contained in the Prospectus.

United Kingdom Taxation

The attention of potential United Kingdom resident Shareholders is drawn to the summary of certain aspects of the anticipated tax treatment in the United Kingdom as set out below.

It is the intention of the Fund to enter into the HMRC reporting fund regime for certain Classes (currently Class I Sterling, Class I US\$, Class A Sterling, Class A US\$, Class F Sterling, Class F US\$, Class S Sterling, and Class S US\$) of the Sub-Fund. Entry into the reporting fund regime will be made for accounting periods commencing from 1 January, 2019, or whenever the Class launches, if later. The Directors intend to take all practicable steps, consistent with applicable laws, regulatory requirements and investment objectives and policies of the Sub-Fund, to facilitate certification as a reporting fund and to retain the reporting fund status for subsequent periods. Please see the section headed "United Kingdom Taxation" on page 88 of the Prospectus for further information.

American Century Advanced Medical Impact Fund Supplement

Class Supplement for Class A US\$ Shares, Class A Euro Shares, and Class A Sterling Shares
("Class A Shares")

This Class Supplement dated 17th December, 2020 should be read in the context of and in conjunction with the Prospectus dated 21st May, 2020 for Nomura Funds Ireland plc ("the Prospectus") and Supplement 30 dated 17th December, 2020 relating to the American Century Advanced Medical Impact Fund (the "Sub-Fund Supplement").

This Class Supplement contains specific information in relation to Class A Shares of American Century Emerging Markets Sustainable Impact Equity Fund (the "Sub-Fund"), a sub-fund of Nomura Funds Ireland plc (the "Fund"), an open-ended umbrella type investment company with segregated liability between each of its Sub-Funds, authorised by the Central Bank as a UCITS.

Designated Currency

Class A Shares shall rank pari passu save for the currency of denomination thereof as set out below:

| Share Class | Designated Currency |
|--------------------|----------------------------|
|--------------------|----------------------------|

| | |
|------------------|----------|
| Class A US\$ | US\$ |
| Class A Euro | Euros |
| Class A Sterling | Sterling |

Minimum Subscription: US\$5,000 (or equivalent)

Minimum Holding: US\$5,000 (or equivalent)

Minimum Transaction Size: US\$2,500 (or equivalent)

Fees: Please refer to the section headed "Fees and Expenses" as set out in the Prospectus and the section titled "Fees and Expenses" in the Sub-Fund's Supplement. In the case of Class A Shares, a sales charge of up to 5% of the Net Asset Value per Share and a conversion fee of up to 5% of the Net Asset Value per Share may be charged.

Investment Manager's Fee: 1.80% of the Net Asset Value of Class A Shares.

Details of Offer:

Class A Shares will be offered to investors from 9am (Irish time) on 18th December, 2020 to 5pm (Irish time) on 18th June, 2021 (the "Initial Offer Period") at the price set out below (the "Initial Offer Price") and subject to acceptance of applications for Shares by the Fund and will be issued for the first time

on the first Dealing Day after expiry of the Initial Offer Period. The Initial Offer Period may be shortened or extended by the Directors in accordance with the Central Bank's requirements. After the closing of the Initial Offer Period, Class A Shares will be issued at the Net Asset Value per Share (plus duties and charges, where relevant).

| Share Class | Initial Offer Price |
|--------------------|----------------------------|
| Class A US\$ | US\$100 |
| Class A Euro | €100 |
| Class A Sterling | £100 |

The Directors reserve the right to differentiate between Shareholders as to and waive or reduce the Minimum Subscription, Minimum Holding and Minimum Transaction Size for certain investors subject to the requirements of the Central Bank.

Reporting Status

It is the intention of the Fund to enter into the HMRC reporting fund regime for Class A Sterling and Class A US\$ of the Sub-Fund. Entry into the reporting fund regime will be made for accounting periods commencing from 1 January, 2020, or whenever the Class launches, if later. The Directors intend to take all practicable steps, consistent with applicable laws, regulatory requirements and investment objectives and policies of the Sub-Fund, to facilitate certification as a reporting fund and to retain the reporting fund status for subsequent periods. In this regard, the attention of investors is drawn to the Section of the Sub-Fund Supplement headed "Taxation".

American Century Advanced Medical Impact Fund Supplement

Class Supplement for Class F US\$ Shares, Class F Euro Shares, and Class F Sterling Shares
("Class F Shares")

This Class Supplement dated 17th December, 2020 should be read in the context of and in conjunction with the Prospectus dated 21st May, 2020 for Nomura Funds Ireland plc ("the Prospectus") and Supplement 30 dated 17th December, 2020 relating to the American Century Advanced Medical Impact Fund (the "Sub-Fund Supplement").

This Class Supplement contains specific information in relation to Class F Shares of American Century Emerging Markets Sustainable Impact Equity Fund (the "Sub-Fund"), a sub-fund of Nomura Funds Ireland plc (the "Fund"), an open-ended umbrella type investment company with segregated liability between each of its Sub-Funds, authorised by the Central Bank as a UCITS.

Designated Currency

Class F Shares shall rank pari passu save for the currency of denomination thereof as set out below:

| Share Class | Designated Currency |
|----------------------------------|--|
| Class F US\$ | US\$ |
| Class F Euro | Euros |
| Class F Sterling | Sterling |
| Minimum Subscription: | US\$10,000,000 (or equivalent) |
| Minimum Holding: | US\$1,000,000 (or equivalent) |
| Minimum Transaction Size: | US\$1,000,000 (or equivalent) |
| Fees: | Please refer to the section headed "Fees and Expenses" as set out in the Prospectus and the section titled "Fees and Expenses" in the Sub-Fund's Supplement. In the case of Class F Shares, no sales charge or conversion fee will be charged. |

Investment Manager's Fee: 0.45% of the Net Asset Value of Class F Shares.

Details of Offer:

Class F shares are only offered in certain limited circumstances at the discretion of Nomura Asset Management U.K. Ltd to investors providing initial funding or seed investment to the Sub-Fund. Class F Shares will be offered until the assets under management of the Class F Shares reaches US\$150 million or the equivalent thereof or for a limited time subject to the discretion of Nomura Asset Management U.K. Ltd.

Class F Shares will be offered to investors from 9am (Irish time) on 18th December, 2020 to 5pm (Irish time) on 18th June, 2021 (the "Initial Offer Period") at the price set out below (the "Initial Offer Price") and subject to acceptance of applications for Shares by the Fund and will be issued for the first time on the first Dealing Day after expiry of the Initial Offer Period. The Initial Offer Period may be shortened or extended by the Directors in accordance with the Central Bank's requirements. After the closing of the Initial Offer Period, Class F Shares will be issued at the Net Asset Value per Share (plus duties and charges, where relevant).

| Share Class | Initial Offer Price |
|--------------------|----------------------------|
| Class F US\$ | US\$100 |
| Class F Euro | €100 |
| Class F Sterling | £100 |

The Directors reserve the right to differentiate between Shareholders as to and waive or reduce the Minimum Subscription, Minimum Holding and Minimum Transaction Size for certain investors subject to the requirements of the Central Bank.

Reporting Status

It is the intention of the Fund to enter into the HMRC reporting fund regime for Class F Sterling and Class F US\$ of the Sub-Fund. Entry into the reporting fund regime will be made for accounting periods commencing from 1 January, 2020, or whenever the Class launches, if later. The Directors intend to take all practicable steps, consistent with applicable laws, regulatory requirements and investment objectives and policies of the Sub-Fund, to facilitate certification as a reporting fund and to retain the reporting fund status for subsequent periods. In this regard, the attention of investors is drawn to the Section of the Sub-Fund Supplement headed "Taxation".

American Century Advanced Medical Impact Fund Supplement

Class Supplement for Class I US\$ Shares, Class I Euro Shares, and Class I Sterling Shares
("Class I Shares")

This Class Supplement dated 17th December, 2020 should be read in the context of and in conjunction with the Prospectus dated 21st May, 2020 for Nomura Funds Ireland plc ("the Prospectus") and Supplement 30 dated 17th December, 2020 relating to the American Century Advanced Medical Impact Fund (the "Sub-Fund Supplement").

This Class Supplement contains specific information in relation to Class I Shares of American Century Emerging Markets Sustainable Impact Equity Fund (the "Sub-Fund"), a sub-fund of Nomura Funds Ireland plc (the "Fund"), an open-ended umbrella type investment company with segregated liability between each of its Sub-Funds, authorised by the Central Bank as a UCITS.

Designated Currency

Class I Shares shall rank pari passu save for the currency of denomination thereof as set out below:

| Share Class | Designated Currency |
|--------------------|----------------------------|
|--------------------|----------------------------|

| | |
|------------------|----------|
| Class I US\$ | US\$ |
| Class I Euro | Euros |
| Class I Sterling | Sterling |

Minimum Subscription: US\$1,000,000 (or equivalent)

Minimum Holding: US\$1,000,000 (or equivalent)

Minimum Transaction Size: US\$250,000 (or equivalent)

Fees: Please refer to the section headed "Fees and Expenses" as set out in the Prospectus and the section titled "Fees and Expenses" in the Sub-Fund's Supplement. In the case of Class I Shares, no sales charge or conversion fee will be charged.

Investment Manager's Fee: 0.90% of the Net Asset Value of Class I Shares.

Details of Offer:

Class I Shares are available to certain financial intermediaries or institutions for distribution to their clients where the investment services provided by these intermediaries or institutions is exclusively remunerated by their clients, and they have separate fee based advisory arrangements with their clients or provide independent advice or discretionary portfolio management.

Class I Shares are also available to other investors or intermediaries at the Board's discretion.

Class I Shares will be offered to investors from 9am (Irish time) on 18th December, 2020 to 5pm (Irish time) on 18th June, 2021 (the "Initial Offer Period") at the price set out below (the "Initial Offer Price") and subject to acceptance of applications for Shares by the Fund and will be issued for the first time on the first Dealing Day after expiry of the Initial Offer Period. The Initial Offer Period may be shortened or extended by the Directors in accordance with the Central Bank's requirements. After the closing of the Initial Offer Period, Class I Shares will be issued at the Net Asset Value per Share (plus duties and charges, where relevant).

| Share Class | Initial Offer Price |
|--------------------|----------------------------|
| Class I US\$ | US\$100 |
| Class I Euro | €100 |
| Class I Sterling | £100 |

The Directors reserve the right to differentiate between Shareholders as to and waive or reduce the Minimum Subscription, Minimum Holding and Minimum Transaction Size for certain investors subject to the requirements of the Central Bank.

Reporting Status

It is the intention of the Fund to enter into the HMRC reporting fund regime for Class I Sterling and Class I US\$ of the Sub-Fund. Entry into the reporting fund regime will be made for accounting periods commencing from 1 January, 2020, or whenever the Class launches, if later. The Directors intend to take all practicable steps, consistent with applicable laws, regulatory requirements and investment objectives and policies of the Sub-Fund, to facilitate certification as a reporting fund and to retain the reporting fund status for subsequent periods. In this regard, the attention of investors is drawn to the Section of the Sub-Fund Supplement headed "Taxation".

American Century Advanced Medical Impact Fund Supplement

Class Supplement for Class S US\$ Shares, Class S Euro Shares, and Class S Sterling Shares
("Class S Shares")

This Class Supplement dated 17th December, 2020 should be read in the context of and in conjunction with the Prospectus dated 21st May, 2020 for Nomura Funds Ireland plc ("the Prospectus") and Supplement 30 dated 17th December, 2020 relating to the American Century Advanced Medical Impact Fund (the "Sub-Fund Supplement").

This Class Supplement contains specific information in relation to Class S Shares of American Century Emerging Markets Sustainable Impact Equity Fund (the "Sub-Fund"), a sub-fund of Nomura Funds Ireland plc (the "Fund"), an open-ended umbrella type investment company with segregated liability between each of its Sub-Funds, authorised by the Central Bank as a UCITS.

Designated Currency

Class S Shares shall rank pari passu save for the currency of denomination thereof as set out below:

| Share Class | Designated Currency |
|----------------------------------|--|
| Class S US\$ | US\$ |
| Class S Euro | Euros |
| Class S Sterling | Sterling |
| Minimum Subscription: | US\$25,000,000 (or equivalent) |
| Minimum Holding: | US\$1,000,000 (or equivalent) |
| Minimum Transaction Size: | US\$250,000 (or equivalent) |
| Fees: | Please refer to the section headed "Fees and Expenses" as set out in the Prospectus and the section titled "Fees and Expenses" in the Sub-Fund's Supplement. In the case of Class S Shares, no sales charge or conversion fee will be charged. |

Investment Manager's Fee: 0.70% of the Net Asset Value of Class S Shares.

Details of Offer:

Class S shares are only offered in certain limited circumstances at the discretion of Nomura Asset Management U.K. Ltd to investors providing initial funding or seed investment to the Sub-Fund.

Class S Shares will be offered to investors from 9am (Irish time) on 18th December, 2020 to 5pm (Irish time) 18th June, 2021 (the "Initial Offer Period") at the price set out below (the "Initial Offer

Price”) and subject to acceptance of applications for Shares by the Fund and will be issued for the first time on the first Dealing Day after expiry of the Initial Offer Period. The Initial Offer Period may be shortened or extended by the Directors in accordance with the Central Bank’s requirements. After the closing of the Initial Offer Period, Class S Shares will be issued at the Net Asset Value per Share (plus duties and charges, where relevant).

| Share Class | Initial Offer Price |
|--------------------|----------------------------|
| Class S US\$ | US\$100 |
| Class S Euro | €100 |
| Class S Sterling | £100 |

The Directors reserve the right to differentiate between Shareholders as to and waive or reduce the Minimum Subscription, Minimum Holding and Minimum Transaction Size for certain investors subject to the requirements of the Central Bank.

Reporting Status

It is the intention of the Fund to enter into the HMRC reporting fund regime for Class S Sterling and Class S US\$ of the Sub-Fund. Entry into the reporting fund regime will be made for accounting periods commencing from 1 January, 2020, or whenever the Class launches, if later. The Directors intend to take all practicable steps, consistent with applicable laws, regulatory requirements and investment objectives and policies of the Sub-Fund, to facilitate certification as a reporting fund and to retain the reporting fund status for subsequent periods. In this regard, the attention of investors is drawn to the Section of the Sub-Fund Supplement headed “Taxation”.